Stock AIMD AINOS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ainos, Inc.

Equities

AIMD

US00902F3038

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-15 pm EDT 		5-day change 1st Jan Change
1.035 USD -0.48% Intraday chart for Ainos, Inc. -1.44% -49.51%
May. 15 Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment MT
May. 15 Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
Top Premarket Decliners
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Premarket Gainers
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
Ainos Regains Compliance With Nasdaq Listing Rule
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Ainos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Ainos, Inc. Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on Veldona
Ainos Says Candidate Treatment for HIV Oral Warts Gets Orphan Drug Designation
Ainos, Inc. Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
Ainos, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform for Broader Industry Adoption
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIMD Stock
  4. News Ainos, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW